通讯作者: 胡伟, 13938592975@139.cpm

DOI：10.12201/bmr.202508.00045

Clinical Efficacy of Penpulimab Combined Chemotherapy in Non-Squamous NSCLC

• 摘要：目的 探讨国产新型PD-1抑制剂派安普利单抗联合化疗治疗晚期非鳞非小细胞肺癌（Non-Small Cell Lung Cancer, NSCLC）治疗中的临床疗效。方法 回顾性选取2021年10月至2022年12月在本院确诊为转移性或局部晚期非鳞NSCLC的患者，分为对照组（接受标准含铂双药化疗）和观察组（接受派安普利单抗联合化疗）。比较两组患者的客观缓解率（Objective response rate, ORR）、无进展生存期（Progression-free survival, PFS）、肺癌相关肿瘤标志物（CYFRA21-1， CEA）水平及免疫功能相关指标（CD3+， CD4+, CD8+细胞阳性率及CD4+/CD8+比值）的变化并评估不良反应的发生情况。结果 经过六个周期治疗，观察组的ORR明显高于对照组（55.6%和34.4%，P=0.029），PFS亦显著延长（17.0个月和11.0个月，P＜0.05）；治疗后，观察组的CYFRA21-1、CEA表达水平显著低于对照组（P＜0.05）；免疫功能分析显示，观察组CD3+, CD4+细胞阳性率、CD4+/CD8+比值较对照组显著升高，而CD8+细胞阳性率显著下降（P<0.05）。安全性分析显示，两组患者在恶心呕吐、贫血、肝肾毒性、皮疹方面差异无统计学意义（P>0.05），但观察组中性粒细胞减少症发生率高于对照组（P<0.05）。结论 在转移性或局部晚期非鳞NSCLC治疗过程中，采用含铂双药联合化疗基础上应用PD-1抑制剂派安普利单抗能够显著提高疗效、优化肿瘤标志物水平、改善机体免疫功能、并延长无进展生存期。

  关键词： 非鳞非小细胞; 派安普利单抗; 化疗; 免疫治疗; 生存期

   

  Abstract: Objective To evaluate the clinical efficacy of Penpulimab, a novel domestic PD-1 inhibitor, combined with chemotherapy in the treatment of advanced non-squamous non-small cell lung cancer (Non-Small Cell Lung Cancer, NSCLC). Methods Patients diagnosed with metastatic or locally advanced non-squamous NSCLC in our hospital from October 2021 to December 2022 were retrospectively selected and divided into a control group (receiving standard platinum-containing dual drug chemotherapy) and an observation group (receiving piamprimab combined chemotherapy). The objective response rate (Objective response rate,ORR), progression-free survival (PFS), tumor markers (CYFRA21-1 and CEA), immune function indicators (CD3+, CD4+, CD8+ cell positivity, and CD4+/CD8+ ratio), and adverse events were compared between the two groups. Results After six cycles of treatment, the ORR in the observation group was significantly higher than that in the control group (55.6% vs. 34.4%, P=0.029), and the PFS was also significantly longer (17.0 months vs. 11.0 months, P<0.05). Post-treatment, CYFRA21-1 and CEA levels were significantly lower in the observation group compared to the control group (P<0.05). Additionally, immune function analysis showed that CD3+ and CD4+ cell positivity and the CD4+/CD8+ ratio significantly increased, while CD8+ cell positivity decreased, with a greater improvement observed in the observation group (P<0.05). Both groups experienced varying degrees of adverse effects; however, symptoms were effectively managed. No statistically significant differences were found between the two groups regarding nausea, vomiting, anemia, hepatotoxicity, nephrotoxicity, or rash (P>0.05), but the incidence of neutropenia was higher in the observation group (P<0.05). Conclusion The combination of Penpulimab with platinum-based chemotherapy significantly improves treatment efficacy, reduces tumor marker levels, enhances immune function, and prolongs progression-free survival in patients with advanced non-squamous NSCLC.

  Key words: Non-squamous NSCLC; Penpulimab; Chemotherapy; Immunotherapy; Survival

  提交时间：2025-08-22

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• 李娜, 罗炳清. 微波消融联合化疗+PD-1抑制剂治疗非小细胞肺癌的临床观察. 2025. doi: 10.12201/bmr.202504.00054

  刘雪杨, 程柯, 许树才. 非小细胞肺癌患者血液高凝状态治疗研究进展. 2025. doi: 10.12201/bmr.202506.00015

  王子婕, 张鑫众. 叶酸受体阳性循环肿瘤细胞与非小细胞肺癌发生发展的研究进展. 2025. doi: 10.12201/bmr.202506.00024

  付思思. 非小细胞肺癌患者肺叶切除术后恶心呕吐Nomogram分析模型构建与验证. 2025. doi: 10.12201/bmr.202507.00001

  郑歆. PD-1免疫诱导治疗在不可切除Ⅲ期NSCLC中的研究进展. 2025. doi: 10.12201/bmr.202501.00025

  徐建杭, 刘亚楠, 詹明, 韩飞. 非奈利酮治疗糖尿病肾病的研究进展与展望. 2024. doi: 10.12201/bmr.202410.00033

  赵静, 黄珺霞, 唐秀花, 王红. HOXA11-AS/miR-149-3p通路在肺鳞状细胞癌中的作用及机制研究. 2022. doi: 10.12201/bmr.202204.00005

  赵浩森, 曲颜丽. 真实世界中局部晚期胃/胃食管结合部腺癌患者术前化疗的疗效及安全性. 2024. doi: 10.12201/bmr.202409.00052

  邹光旭, 侯宇, 李涌, 周伟兴, 李耀钊, 李立▲. 冷冻消融诱导的免疫效应及联合免疫治疗研究进展. 2025. doi: 10.12201/bmr.202503.00061

  蓝清华. 重组人粒细胞-巨噬细胞集落刺激因子联合双歧杆菌治疗化疗后口腔黏膜炎的临床研究. 2025. doi: 10.12201/bmr.202505.00045

• 序号	提交日期	编号	操作
  1	2025-04-14	bmr.202508.00045V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论